Iberdomide Capsules 0.75 mg, 1 mg Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 0.75 mg, 1 mg
Reference Brands: Zenbexus
Category: Oncology Cancer Care
Iberdomide (Zenbexus, Bristol Myers Squibb) is an oral CELMoD for multiple myeloma, used with daratumumab and dexamethasone. The US FDA approved it in August 2026. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers, API makers and licensees preparing for patent expiry.
Manufacture or export Iberdomide Capsules? List it or send an offer →
Product Description:
Iberdomide is a cereblon E3 ligase modulator (CELMoD), a successor to lenalidomide and pomalidomide. It binds cereblon much more strongly and causes faster, deeper breakdown of Ikaros and Aiolos, two proteins myeloma cells depend on. It also stimulates the immune system against the tumour, and it can work in myeloma that has become resistant to the older drugs.
The US FDA granted iberdomide accelerated approval as Zenbexus in August 2026 for adults with multiple myeloma who have had at least one prior line of therapy, in combination with subcutaneous daratumumab and dexamethasone. It is supplied as 0.75 mg and 1 mg capsules. Like other drugs in its family it can harm an unborn baby, so pregnancy prevention is required.
Sourcing and licensing notes. Iberdomide is patented and made only by Bristol Myers Squibb; there is no generic. Generic lenalidomide and pomalidomide are widely available, and we supply those too. We handle enquiries for authorised supply of Zenbexus and connect developers and licensees interested in the molecule ahead of patent expiry.
How Iberdomide Capsules is supplied today, and licensing ahead of patent expiry
Where iberdomide is approved
Checked 3 Oct 2026| Market | Status | Brand · regulator · date |
|---|---|---|
| United States | Approved | Zenbexus · FDA · Aug 2026 (accelerated) |
| Generic / biosimilar | None | None approved as of the check date |
Not approved in your country? A hospital or doctor can often still import it for a named patient, through a special-access, import-permit or compassionate-use route. We confirm which route applies in your country and the documents needed before quoting. Ask about named-patient supply →
Frequently Asked Questions
Multiple myeloma after at least one prior treatment, together with daratumumab and dexamethasone.
Zenbexus, from Bristol Myers Squibb. The US FDA approved it in August 2026.
All three act on cereblon. Iberdomide binds it more strongly and is designed to work where the older drugs have stopped working.
No. It is patented. We handle authorised-supply enquiries and connect developers and licensees preparing for patent expiry.
Related Products
Sonrotoclax Tablets
Strength:
1 mg, 5 mg, 20 mg, 80 mg
Form: Tablets
Reference Brands: Beqalzi
View DetailsSunvozertinib Tablets
Strength:
150 mg, 200 mg
Form: Tablets
Reference Brands: Zegfrovy
View Details
Panobinostat Lactate
Strength:
10 mg, 15 mg, 20 mg
Form: Capsules
Reference Brands: Farydak (USA/EU)
View Details
Usually answered within 48 hours | GMP documents shared before you commit
